Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric…
Max India Limited’s Rights Issue: 1.45 Times Oversubscription Signals Strong Investor Confidence
Max India Limited (MIL) has announced the successful closure of its Rights…